Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced on May 6, 2026, that its compensation committee granted an inducement stock option to Daniel Keefe, the newly hired Commercial Director for the Western U.S. The option to purchase 17,000 shares of common stock was granted on May 5, 2026, at an exercise price of $3.20 per share, matching the closing price on that date. This grant, made in accordance with Nasdaq Listing Rule 5635(c)(4), served as a material inducement for Mr. Keefe to join the company.
The option vests over four years, with one-fourth vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the subsequent three years, contingent on continued employment. The option carries a 10-year term and is governed by an inducement stock option agreement. This move underscores Aclarion's strategy to expand its commercial team, particularly in the Western U.S., to meet rising demand for its Nociscan platform, which has seen triple-digit growth in utilization.
Aclarion's Nociscan is a Software-as-a-Service (SaaS) platform that uses magnetic resonance spectroscopy (MRS) data from MRI machines to noninvasively help physicians identify painful versus nonpainful discs in the lumbar spine. The platform applies proprietary signal processing and augmented intelligence algorithms to analyze chemical biomarkers associated with disc pain, providing critical insights for optimizing treatment strategies for chronic low back pain. The company's focus on addressing the chronic low back pain market positions it to capitalize on the growing need for precise diagnostic tools.
The expansion of the commercial team, including the appointment of a dedicated director for the Western U.S., signals Aclarion's commitment to scaling its sales and marketing efforts. This follows the company's recent milestones and increasing adoption of Nociscan by healthcare providers. For more information about Aclarion and its technology, visit www.aclarion.com.
Forward-looking statements in this release, such as those regarding increasing demand for Nociscan, are subject to risks and uncertainties. The company cautions investors to review risk factors detailed in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. Aclarion undertakes no obligation to update forward-looking statements. The latest news and updates related to Aclarion are available at https://tinyurl.com/aconnewsroom.
